Mangoceuticals, Inc. entered into a Securities Purchase Agreement with an institutional accredited investor to sell 1,500 shares of Series B Convertible Preferred Stock and warrants to purchase up to 3,300,000 shares of common stock for a total purchase price of $1,500,000.